Biotech Values

[lasers]

This is the $VCEL Clinical Trial that we are waiting for results from the Feb 2017 completion date.

An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) (ixCELL DCM)

https://clinicaltrials.gov/ct2/show/NCT01670981?term=vericel+and+Ixcell&rank=1

Enrollment: 114
Study Start Date: October 2012
Estimated Study Completion Date: February 2017
Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)

This study is designed to assess the efficacy, safety and tolerability of ixmyelocel-T compared to placebo (vehicle control) when administered via transendocardial catheter-based injections to patients with end stage heart failure due to IDCM, who have no reasonable revascularization options (either surgical or percutaneous interventional) likely to provide clinical benefit.

For all of the 114 patients, $VCEL's treatment is/was their last hope to live.